Adagrasib vs Fulzerasib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline

Adagrasib · Krazati

Marketed by Bristol-Myers Squibb and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04685135 · Phase 3 · active, not recruiting

This was a randomized phase 3 trial of 453 people against an active comparator (docetaxel). The progression-free survival endpoint, reviewed by a blinded independent committee, was clearly met, but treatment was open-label, so it is graded below the highest tier.

Next expected readout: January 2027 · NCT06026410 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) as Per Blinded Independent Central Review (From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)): Progression-Free Survival (PFS) as Per Blinded Independent Central Review (From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)): Adagrasib 5.49 months (95% CI 4.53 to 6.67) | Docetaxel 3.84 months (95% CI 2.73 to 4.73) (met)

Result source: NCT04685135

Fulzerasib · Dupert

Marketed by Innovent Biologics under a licence from GenFleet Therapeutics

Phase 2 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05756153 · Phase 1/2 · completed

KROCUS was a single-arm, open-label Phase 1b/2 trial of fulzerasib plus cetuximab in previously untreated KRAS G12C-mutated non-small-cell lung cancer, with 47 patients treated at 30 centres. The Phase 2 primary endpoint was the investigator-assessed objective response rate, and the confirmed rate was 69% (90% CI 56 to 80). With no comparator arm and no formal success threshold reported, no result can be called met or missed. Treatment-related adverse events occurred in 87% of patients, grade 3 in 15%, with no grade 4 or 5 events. The figures come from the final peer-reviewed report (Gregorc et al., Lancet Oncol 2026).

Single-arm response rate with no comparator and no formal statistical threshold.

Next expected readout: March 2027 · NCT07492342 (registry estimate)

Reported efficacy

Phase Ib: adverse events (28 days); Phase II: objective response rate (up to 1 year after last patient in): Confirmed investigator-assessed objective response rate per RECIST 1.1 (Phase 2 primary), fulzerasib 600 mg twice daily plus cetuximab, single arm, first-line KRAS G12C NSCLC: 69% (90% CI 56 to 80); 47 patients treated; data cutoff 14 January 2025. (not_applicable)

Result source: NCT05756153

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAdagrasibFulzerasib
PFS, median—Trial running · NCT04613596—Trial running · NCT07601048
OS, median—Trial running · NCT04613596—Trial running · NCT07601048
ORR—Trial running · NCT04613596—Trial running · NCT07601048
Duration of response, median—Trial running · NCT04613596—Trial running · NCT07601048

PFS, median

Adagrasib
—Trial running · NCT04613596
Fulzerasib
—Trial running · NCT07601048

OS, median

Adagrasib
—Trial running · NCT04613596
Fulzerasib
—Trial running · NCT07601048

ORR

Adagrasib
—Trial running · NCT04613596
Fulzerasib
—Trial running · NCT07601048

Duration of response, median

Adagrasib
—Trial running · NCT04613596
Fulzerasib
—Trial running · NCT07601048
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Adagrasib: registry results are on file for Non-Small Cell Lung Cancer, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Fulzerasib
Confirmed investigator-assessed objective response rate per RECIST 1.1 (Phase 2 primary), fulzerasib 600 mg twice daily plus cetuximab, single arm, first-line KRAS G12C NSCLC: 69% (90% CI 56 to 80); 47 patients treated; data cutoff 14 January 2025. NCT05756153 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Adagrasib's landscape · Fulzerasib's landscape